INCYTE – JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential!

August 2013 | 3 pages | ID: I63B7D8A1E7EN
MP Advisors

Abstracts

Positive interim Overall Survival analysis data from the PhII, RECAP trial of Ruxolitinib (L – JAKAFI for MF, oral JAK 1/2 inhibitor, PhII/III in PV/ET, partnered with Novartis for Ex-US rights) in combination with capecitabine in recurrent or treatment-refractory metastatic pancreatic cancer pts is a pleasant surprise. The hazard ratio for overall survival in the intent-to-treat (ITT) population was 0.79, and in a pre-specified subgroup analysis (pts identified prospectively as most likely to benefit from JAK pathway inhibition, 50% of the enrolled population), the HR for OS was 0.47 (one-sided p=0.005). With an ‘Orphan drug’ status for this indication and no approved drug for metastatic pancreatic cancer, label expansion could make. For more details, please read our report released o 21st Aug., 2013 on INCY, titled “JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential!”